SCHEMBL4374046

SCHEMBL4374046

COc1cc2c(Oc3ccc4[nH]ccc4c3)ncnc2cc1OCCN1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.54
RAF1 P04049 6/20 0.53
BRAF P15056 5/20 0.53
PDGFRB P09619 2/20 0.51
KDR P35968 6/20 0.51
EPHB4 P54760 2/20 0.51
EPHA2 P29317 1/20 0.51
EGFR P00533 4/20 0.49
FGFR1 P11362 2/20 0.49
FLT1 P17948 2/20 0.49
FLT4 P35916 2/20 0.49
MET P08581 2/20 0.49
PLK4 O00444 1/20 0.49
GAK O14976 1/20 0.49
EPHB6 O15197 1/20 0.49
RIPK2 O43353 1/20 0.49
ERN1 O75460 1/20 0.49
STK10 O94804 1/20 0.49
MAP4K4 O95819 1/20 0.49
CHEK2 O96017 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4379769 0.96 SRC (0.60) SRCRAF1BRAFPDGFRBKDR
SCHEMBL4377420 0.92 FLT4 (0.57) SRCPDGFRBKDREPHB4EGFR
SCHEMBL4374025 0.92 KDR (0.56) SRCRAF1BRAFPDGFRBKDR
SCHEMBL4380889 0.92 ABCB11 (0.57) SRCBRAFPDGFRBKDREPHB4
SCHEMBL4388812 0.91 SRC (0.61) SRCRAF1BRAFPDGFRBKDR
SCHEMBL4373064 0.88 FLT4 (0.62) SRCPDGFRBKDREPHB4EGFR
SCHEMBL4382463 0.88 KDR (0.58) SRCRAF1BRAFPDGFRBKDR
SCHEMBL4374150 0.87 ABCB11 (0.63) SRCPDGFRBKDREPHB4EGFR
SCHEMBL4375714 0.87 KDR (0.62) SRCRAF1BRAFPDGFRBKDR
SCHEMBL4378879 0.86 EGFR (0.52) SRCRAF1BRAFPDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR SRC 1517/4885RAF1 46/4885BRAF 65/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 SRC 1276/4885RAF1 997/4885BRAF 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.